Amgen terminates Crohn's disease collaboration with TScan; effective Nov 10, 2026

TScan Therapeutics, Inc.

Amgen gave notice Aug 12, 2026 to terminate Research Collaboration and License Agreement; effective Nov 10, 2026.
No early termination penalty; TScan received $30M upfront in 2023, potential milestones over $500M now unlikely.
Collaboration used TScan's target discovery platform for Crohn's disease; Amgen had exclusive worldwide license.
TScan expects no future milestone/royalty payments unless Amgen continues to exploit product candidates.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.